Genmab Initiates Ofatumumab Front Line NHL Study

Copenhagen, Denmark (ots/PRNewswire) -

- Summary: Genmab has Initiated a Phase II Study of Ofatumumab in
Combination With CHOP as Front Line Treatment of Follicular NHL.

Genmab A/S (CSE: GEN) announced today it has initiated a Phase II
study of ofatumumab (HuMax-CD20(R)) in combination with
cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) in
patients with previously untreated follicular non-Hodgkin's lymphoma
(NHL). A total of 56 patients will be enrolled in the study which is
being conducted under Genmab's collaboration with GlaxoSmithKline.

"We are pleased to begin this study of ofatumumab for front line
treatment offollicular NHL," said Lisa N. Drakeman, Ph.D., Chief
Executive Officer of Genmab, "which we hope may be more effective
than currently available treatment."

About the trial

Patients in this open label study will be randomized into two dose
groups of 28patients each and will receive 6 infusions of ofatumumab
in combination with CHOP. Each patient will receive 300 mg of
ofatumumab at the first infusion, followed by 5 subsequent infusions
of either 500 or 1000 mg of ofatumumab every3 weeks, in combination
with 6 cycles of CHOP. Disease status will be assessedat three months
following the last treatment and then every three months until month
24, and every 6 months thereafter until 60 months or initiation of
alternative treatment.

The objective of the study is to determine the efficacy of two
dose regimens of ofatumumab in combination with CHOP in previously
untreated follicular NHL patients. The primary endpoint in the study
is objective response from start of treatment until 3 months after
last treatment assessed according to the standardized response
criteria for NHL at 30 weeks.

About Genmab A/S

Genmab A/S is a biotechnology company that creates and develops
human antibodies for the treatment of life-threatening and
debilitating diseases. Genmab has numerous products in development
to treat cancer, infectious disease, rheumatoid arthritis and other
inflammatory conditions, and intends to continue assembling a broad
portfolio of new therapeutic products. In addition, Genmab has
developed UniBody(TM), a new proprietary technology that creates
astable, smaller antibody format. Genmab has operations in Europe and
the US.For more information about Genmab, visit www.genmab.com.

This press release contains forward looking statements. The words
"believe","expect", "anticipate", "intend" and "plan" and similar
expressions identify forward looking statements. Actual results or
performance may differ materially from any future results or
performance expressed or implied by such statements. The important
factors that could cause our actual results or performance to differ
materially include, among others, risks associated with product
discovery and development, uncertainties related to the outcome and
conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market
acceptance of our products, our inability to manage growth, the
competitive environment in relation to our business area and markets,
our inability to attract and retain suitably qualified personnel,
the unenforceability or lack of protection of our patents and
proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products
obsolete, and other factors. Genmab is not under an obligation to
up-date statements regarding the future following the publication of
this release; nor to confirm such statements in relation to actual
results, unless this is required by law. Genmab(R); the Y- shaped
Genmab logo(R); HuMax(R); HuMax-CD4(R); HuMax-CD20(R);HuMax-EGFr(TM);
HuMax-Inflam(TM); HuMax-TAC(TM); HuMax-HepC(TM),HuMax-CD38(TM);
HuMax- ZP3(TM); and UniBody(TM) are all trademarks of GenmabA/S.

Contact:
Helle Husted
Sr. Director
Investor Relations
T: +45-33-44-77-30
M:+45-25-27-47-13
E: hth@genmab.com Stock
Exchange Release no. 26/2007

ots Originaltext: Genmab A/S
Im Internet recherchierbar: http://www.presseportal.de

Contact:
Contact: Helle Husted, Sr. Director, Investor Relations, T:
+45-33-44-77-30, M:+45-25-27-47-13, E: hth@genmab.com, Exchange
Release no. 26/2007